Cytokeratin 5 Antibody (G-2): sc-377431

Cytokeratin 5 Antibody (G-2) is a mouse monoclonal IgG2a antibody that detects Cytokeratin 5 in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Cytokeratin 5 is a vital component of the cytoskeletal structure in epithelial cells, primarily located in the basal layer of stratified epithelia, where Cytokeratin 5 plays a crucial role in maintaining cellular integrity and resilience against mechanical stress. This localization is particularly important as Cytokeratin 5 contributes to the overall stability of epithelial tissues, which are often subjected to physical abrasion and injury. Furthermore, Cytokeratin 5 expression serves as a key marker for identifying basal cells in various tissues, making anti-Cytokeratin 5 antibody (G-2) invaluable in studying epithelial differentiation and characterizing malignant tumors. Notably, mutations in the gene encoding Cytokeratin 5 (KRT5) can lead to the autosomal dominant disorder epidermolysis bullosa, underscoring Cytokeratin 5′s significance in both health and disease. Anti-Cytokeratin 5 antibody (G-2) serves as an essential tool for researchers investigating epithelial biology and related pathologies.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Cytokeratin 5 Antibody (G-2) References:

1. The expression of p63 and cytokeratin 5 in mixed tumors of the canine mammary gland provides new insights into the histogenesis of these neoplasms.  |  Ramalho, LN., et al. 2006. Vet Pathol. 43: 424-9. PMID: 16846983
2. Cytokeratin 5 positive cells represent a steroid receptor negative and therapy resistant subpopulation in luminal breast cancers.  |  Kabos, P., et al. 2011. Breast Cancer Res Treat. 128: 45-55. PMID: 20665103
3. Role of p40 and cytokeratin 5/6 in the differential diagnosis of sinonasal undifferentiated carcinoma.  |  Singh, L., et al. 2014. Ann Diagn Pathol. 18: 261-5. PMID: 25017972
4. Cytokeratin 5/6 fingerprinting in HER2-positive tumors identifies a poor prognosis and trastuzumab-resistant basal-HER2 subtype of breast cancer.  |  Martin-Castillo, B., et al. 2015. Oncotarget. 6: 7104-22. PMID: 25742793
5. Expression patterns of cytokeratin 5/6 and p63 in thyroid sporadic nodular goiter.  |  Handra-Luca, A. 2016. Minerva Endocrinol. 41: 140-2. PMID: 26878564
6. Expression of c-kit and Cytokeratin 5 in the Submandibular Gland after Release of Long-Term Ligation of the Main Excretory Duct in Mice.  |  Watanabe, H., et al. 2017. Acta Histochem Cytochem. 50: 111-118. PMID: 28744028
7. β cells can be generated from cytokeratin 5-positive cells after cerulein-induced pancreatitis in adult mice.  |  Shi, Q., et al. 2018. Biochem Biophys Res Commun. 496: 114-119. PMID: 29307825
8. A combination of cytokeratin 5/6, p63, p40 and MUC5AC are useful for distinguishing squamous cell carcinoma from adenocarcinoma of the cervix.  |  Li, H., et al. 2020. Diagn Pathol. 15: 104. PMID: 32843061
9. Prognostic Value Of Basal Markers (Epidermal Growth Factor Receptor 'EGFR' And Cytokeratin 5/6) Expression In Triple-Negative Invasive Breast Cancer.  |  ElFeky, AW., et al. 2023. J Pak Med Assoc. 73(Suppl 4): S161-S166. PMID: 37482851
10. Increase of KLK7, cytokeratin 5/6, and elafin expression in head and neck squamous cell carcinoma compared with lung squamous cell carcinoma.  |  Shanmugam, A., et al. 2024. J Histotechnol. 47: 80-86. PMID: 38189409

The preferred Cytokeratin 5 antibody is Cytokeratin 5 Antibody (RCK103): sc-32721.